Intravesical dimethyl sulfoxide inhibits acute and chronic bladder inflammation in transgenic experimental autoimmune cystitis models.
New animal models are greatly needed in interstitial cystitis/painful bladder syndrome (IC/PBS) research. We recently developed a novel transgenic cystitis model (URO-OVA mice) that mimics certain key aspects of IC/PBS pathophysiology. This paper aimed to determine whether URO-OVA cystitis model was responsive to intravesical dimethyl sulfoxide (DMSO) and if so identify the mechanisms of DMSO action. URO-OVA mice developed acute cystitis upon adoptive transfer of OVA-specific OT-I splenocytes. Compared to PBS-treated bladders, the bladders treated with 50% DMSO exhibited markedly reduced bladder histopathology and expression of various inflammatory factor mRNAs. Intravesical DMSO treatment also effectively inhibited bladder inflammation in a spontaneous chronic cystitis model (URO-OVA/OT-I mice). Studies further revealed that DMSO could impair effector T cells in a dose-dependent manner in vitro. Taken together, our results suggest that intravesical DMSO improves the bladder histopathology of IC/PBS patients because of its ability to interfere with multiple inflammatory and bladder cell types.
Department of Urology, Northwestern University, Chicago, IL 60611-3008, USA.
Ronald
R
Kim
Wujiang
W
Liu
Xiaohong
X
Chen
Karl J
KJ
Kreder
Yi
Y
Luo
D000208:Acute Disease; D000818:Animals; D001327:Autoimmune Diseases / Q000235:genetics*; D002908:Chronic Disease; D003556:Cystitis / Q000235:genetics*; D004121:Dimethyl Sulfoxide / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D000939:Epitopes; D005260:Female; D007249:Inflammation; D051379:Mice; D008822:Mice, Transgenic; D013154:Spleen / Q000166:cytology; D001745:Urinary Bladder Diseases / Q000276:immunology*
D000939:Epitopes; D004121:Dimethyl Sulfoxide